Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3(1 Suppl):S21-35.

CAS  PubMed  PubMed Central  Google Scholar 

Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834–48.

CAS  PubMed  Google Scholar 

Gherardi E, Birchmeier W, Birchmeier C, Vande WG. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103.

CAS  PubMed  Google Scholar 

Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18(6):341–58.

CAS  PubMed  Google Scholar 

Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A. 1997;94(21):11445–50.

CAS  PubMed  PubMed Central  Google Scholar 

Fu J, Su X, Li Z, Deng L, Liu X, Feng X, et al. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene. 2021;40(28):4625–51.

CAS  PubMed  Google Scholar 

Scagliotti G, Pawel JV, Novello S, Ramlau R, Favaretto A, Barlesi F, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non–small-cell lung cancer. J Clin Oncol. 2015;33(24):2667–74.

CAS  PubMed  Google Scholar 

Spigel DR, Edelman MJ, O’Byrne K, Paz-Ares L, Mocci S, Phan S, et al. Results From the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV Non-small-cell lung cancer: METLung. J Clin Oncol. 2017;35(4):412–20.

CAS  PubMed  Google Scholar 

Hughes VS, Siemann DW. Have clinical trials properly assessed c-Met inhibitors? Trends Cancer. 2018;4(2):94–7.

CAS  PubMed  PubMed Central  Google Scholar 

Paik PK, Drilon A, Fan P-D, Yu H, Rekhtman N, Ginsberg MS, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842–9.

CAS  PubMed  PubMed Central  Google Scholar 

Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5(8):850–9.

CAS  PubMed  Google Scholar 

Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994;77(2):261–71.

CAS  PubMed  Google Scholar 

Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene. 1994;9(1):49–57.

CAS  PubMed  Google Scholar 

Nakayama M, Sakai K, Yamashita A, Nakamura T, Suzuki Y, Matsumoto K. Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes. Cytokine. 2013;62(3):446–52.

CAS  PubMed  Google Scholar 

Li J, Hu K, Zhou L, Huang J, Zeng S, Xu Z, et al. Spectrum of mesenchymal-epithelial transition aberrations and potential clinical implications: insights from integrative pancancer analysis. Front Oncol. 2020;10: 560615.

PubMed  PubMed Central  Google Scholar 

Li Y, Li M, Zhang Y, Hao X, Zhang Y, Liang X, et al. Genomic and clinical characteristics of MET alterations in solid tumors among the 10,475 Chinese patients. J Clin Oncol. 2022;40(16_suppl):3115.

Google Scholar 

Cheng T, Gu Z, Song D, Liu S, Tong X, Wu X, et al. Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib. J Cancer. 2021;12(3):644–51.

CAS  PubMed  PubMed Central  Google Scholar 

Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, et al. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer. 2017;111:143–9.

PubMed  Google Scholar 

Sterlacci W, Fiegl M, Gugger M, Bubendorf L, Savic S, Tzankov A. MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC. Virchows Arch. 2017;471(1):49–55.

CAS  PubMed  Google Scholar 

Xu Z, Li H, Dong Y, Cheng P, Luo F, Fu S, et al. Incidence and PD-L1 expression of MET 14 skipping in Chinese population: a non-selective NSCLC cohort study using RNA-based sequencing. Onco Targets Ther. 2020;13:6245–53.

CAS  PubMed  PubMed Central  Google Scholar 

Champagnac A, Bringuier P-P, Barritault M, Isaac S, Watkin E, Forest F, et al. Frequency of MET exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients. J Thorac Dis. 2020;12(5):2172–8.

PubMed  PubMed Central  Google Scholar 

Watermann I, Schmitt B, Stellmacher F, Müller J, Gaber R, Kugler C, et al. Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? Diagn Pathol. 2015;10(1):130.

CAS  PubMed  PubMed Central  Google Scholar 

Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, et al. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016;7(34):54627–31.

PubMed  PubMed Central  Google Scholar 

Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, et al. c-MET overexpression in colorectal cancer: a poor prognostic factor for survival. Clin Colorectal Cancer. 2018;17(3):165–9.

PubMed  Google Scholar 

Yang Y, Wang C, Dai C, Liu X, Li W, Huang M, et al. Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1. Acta Biochim Biophys Sin (Shanghai). 2021;53(5):547–57.

CAS  PubMed  Google Scholar 

Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, et al. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. Ann Oncol. 2016;27(1):127–33.

CAS  PubMed  Google Scholar 

Aparicio T, Cozic N, de la Fouchardière C, Meriaux E, Plaza J, Mineur L, et al. The activity of crizotinib in chemo-refractory MET-amplified esophageal and gastric adenocarcinomas: results from the AcSé-Crizotinib Program. Target Oncol. 2021;16(3):381–8.

PubMed  PubMed Central  Google Scholar 

Lee J, Ou SH, Lee JM, Kim HC, Hong M, Kim SY, et al. Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget. 2015;6(29):28211–22.

PubMed  PubMed Central  Google Scholar 

de Melo GD, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, et al. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer. 2014;14(6):468–74.

Google Scholar 

Zagouri F, Brandstetter A, Moussiolis D, Chrysikos D, Dimitrakakis C, Tsigginou A, et al. Low protein expression of MET in ER-positive and HER2-positive breast cancer. Anticancer Res. 2014;34(3):1227–31.

PubMed  Google Scholar 

Van den Bossche V, Jadot G, Grisay G, Pierrard J, Honoré N, Petit B, et al. c-MET as a potential resistance mechanism to everolimus in breast cancer: from a case report to patient cohort analysis. Target Oncol. 2020;15(1):139–46.

PubMed  Google Scholar 

Zagouri F, Bago-Horvath Z, Rössler F, Brandstetter A, Bartsch R, Papadimitriou CA, et al. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer. 2013;108(5):1100–5.

CAS  PubMed  PubMed Central  Google Scholar 

Kim Y, Bang SS, Jee S, Park S, Shin SJ, Jang K. Prevalence and clinicopathological significance of MET overexpression and gene amplification in patients with gallbladder carcinoma. Cancer Res Treat. 2020;52(2):481–91.

CAS  PubMed  Google Scholar 

Kim Y, Jee S, Kim H, Paik SS, Choi D, Yoo SH, et al. EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance. Oncologist. 2024;29(8):e1051–60.

PubMed  PubMed Central  Google Scholar 

de Bitter TJJ, de Reuver PR, de Savornin Lohman EAJ, Kroeze LI, Vink-Börger ME, van Vliet S, et al. Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients. npj Precis Oncol. 2022;6(1):83.

PubMed  PubMed Central  Google Scholar 

Yang L, Guo T, Jiang S, Yang Z. Expression of ezrin, HGF and c-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder. Hepatogastroenterology. 2012;59(118):1769–75.

PubMed